Purified protein derivative testing and tuberculosis preventive therapy for HIV-infected patients in New York City
- 1 October 1998
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 12 (15) , 2017-2023
- https://doi.org/10.1097/00002030-199815000-00013
Abstract
To determine whether Centers for Disease Control and Prevention recommendations for purified protein derivative (PPD) testing and tuberculosis (TB) preventive therapy for PPD-positive patients are implemented in HIV clinics. Retrospective medical chart review. Ten hospital-based HIV clinics in New York City. A total of 2397 patients with a first clinic visit in 1995. PPD testing of eligible patients, and recommendation of preventive therapy and completion of regimen in PPD-positive patients. Outpatient medical records were abstracted for TB history, PPD testing, TB preventive therapy, and patient demographic, social and clinical characteristics. Multivariate analyses were performed using logistic regression. Of 1342 patients with an indication for a PPD test, 865 (64%) were PPD tested in the clinic and 757 (88%) returned to have it read. Factors strongly associated with PPD testing in the clinic were number of visits, same sex behavior with men, and CD4+ lymphocyte count above 200 × 106/l. Preventive therapy was recommended for 80% of newly identified PPD-positive patients and 22% of previously identified PPD-positive patients. Of 119 patients on preventive therapy in the clinic, 49 (41%) completed the regimen, 50 (42%) were lost to follow-up, and 20 (17%) discontinued therapy or their status could not be determined. A significant number of missed opportunities to implement TB prevention practices were identified in HIV clinics. Focused attention in HIV clinics, and increased collaboration between HIV clinics and TB control programs may be needed to increase adherence to prevention guidelines.Keywords
This publication has 16 references indexed in Scilit:
- Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapyNature Medicine, 1998
- Antiretroviral Therapy for HIV Infection in 1997JAMA, 1997
- Reliability of anergy skin testing in persons with HIV infection. The pulmonary Complications of HIV Infection Study Group.American Journal of Respiratory and Critical Care Medicine, 1996
- Use of Preventive Interventions by Persons Infected with Type-1 Human Immunodeficiency Virus (HIV-1)American Journal of Preventive Medicine, 1994
- Tuberculin and Anergy Testing in HIV-Seropositive and HIV-Seronegative PersonsAnnals of Internal Medicine, 1993
- Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infectionThe Lancet, 1993
- Preventive medicine for HIV-infected patientsJournal of General Internal Medicine, 1992
- Isoniazid as Preventive Therapy in HIV-Infected Intravenous Drug AbusersPublished by American Medical Association (AMA) ,1991
- A Prospective Study of the Risk of Tuberculosis among Intravenous Drug Users with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1989
- EPIDEMIOLOGY OF TUBERCULOSIS IN THE UNITED STATESEpidemiologic Reviews, 1989